Trastuzumab improves tumor perfusion and vascular delivery of cytotoxic therapy in a murine model of HER2+ breast cancer: preliminary results

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Breast Cancer Research and Treatment

• Publication date

  2016-01-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s10549-016-3680-8PMID 26791520PMCID PMC4833210
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Multiparametric Magnetic Resonance Imaging for Predicting Pathological Response After the First Cycle of Neoadjuvant Chemotherapy in Breast Cancer

  2015cited by this paper
• HER2-directed therapy: current treatment options for HER2-positive breast cancer

  2015cited by this paper
• Utility of [18 F]FLT-PET to Assess Treatment Response in Trastuzumab-Resistant and Trastuzumab-Sensitive HER2-Overexpressing Human Breast Cancer Xenografts

  2015cited by this paper
• Evaluating treatment response using DW-MRI and DCE-MRI in trastuzumab responsive and resistant HER2-overexpressing human breast cancer xenografts

  2014cited by this paper
• In vivo hyperspectral imaging of microvessel response to trastuzumab treatment in breast cancer xenografts.

  2014cited by this paper
• Assessing the reproducibility of dynamic contrast enhanced magnetic resonance imaging in a murine model of breast cancer

  2013cited by this paper
• Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers.

  2013cited by this paper
• Modifications in dynamic contrast-enhanced magnetic resonance imaging parameters after α-particle-emitting ²²⁷Th-trastuzumab therapy of HER2-expressing ovarian cancer xenografts.

  2013cited by this paper
• SnapShot: Tumor angiogenesis.

  2012cited by this paper
• Practical Dynamic Contrast Enhanced MRI in Small Animal Models of Cancer: Data Acquisition, Data Analysis, and Interpretation

  2012cited by this paper
• Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease.

  2012cited by this paper
• Pharmacokinetic parameters derived from dynamic contrast enhanced MRI of cervical cancers predict chemoradiotherapy outcome.

  2012cited by this paper
• The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy

  2012cited by this paper
• Trastuzumab: Updated Mechanisms of Action and Resistance in Breast Cancer

  2012cited by this paper
• Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy--results from ACRIN 6657/I-SPY TRIAL.

  2012cited by this paper
• Pharmacokinetic parameters from 3‐Tesla DCE‐MRI as surrogate biomarkers of antitumor effects of bevacizumab plus FOLFIRI in colorectal cancer with liver metastasis

  2012cited by this paper
• Normalization of the vasculature for treatment of cancer and other diseases.

  2011cited by this paper
• 99mTc-(CO)3 His-Annexin A5 Micro-SPECT Demonstrates Increased Cell Death by Irinotecan During the Vascular Normalization Window Caused by Bevacizumab

  2011cited by this paper
• Augmented inhibition of angiogenesis by combination of HER2 antibody chA21 and trastuzumab in human ovarian carcinoma xenograft

  2010cited by this paper
• Noninvasive evaluation of antiangiogenic effect in a mouse tumor model by DCE-MRI with Gd-DTPA cystamine copolymers.

  2010cited by this paper
• Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer.

  2009cited by this paper
• Specific blockade of VEGF and HER2 pathways results in greater growth inhibition of breast cancer xenografts that overexpress HER2

  2008cited by this paper
• Her2-positive breast cancer: herceptin and beyond.

  2008cited by this paper
• DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents

  2007cited by this paper
• Dynamic Contrast Enhanced Magnetic Resonance Imaging in Oncology: Theory, Data Acquisition, Analysis, and Examples.

  2007cited by this paper
• A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes.

  2006cited by this paper
• Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer.

  2006cited by this paper
• HER2 therapy: Molecular mechanisms of trastuzumab resistance

  2006cited by this paper
• Trastuzumab in the treatment of breast cancer.

  2005cited by this paper
• Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy

  2005cited by this paper
• Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.

  2005cited by this paper
• Dynamic contrast-enhanced magnetic resonance imaging at 1.5 Tesla with gadopentetate dimeglumine to assess the angiostatic effects of anginex in mice.

  2004cited by this paper
• Biologic and therapeutic role of HER2 in cancer

  2003cited by this paper
• Combined trastuzumab and paclitaxel treatment better inhibits ErbB‐2‐mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone

  2003cited by this paper
• Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab

  2003cited by this paper
• Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.

  2002cited by this paper
• Tumour biology: Herceptin acts as an anti-angiogenic cocktail

  2002cited by this paper
• Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy

  2001cited by this paper
• Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors.

  2000cited by this paper
• Estimating kinetic parameters from dynamic contrast‐enhanced t1‐weighted MRI of a diffusable tracer: Standardized quantities and symbols

  1999cited by this paper
• Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts.

  1998cited by this paper
• Correlation of dynamic contrast-enhanced magnetic resonance imaging with histologic tumor grade: comparison of macromolecular and small-molecular contrast media

  1998cited by this paper
• Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies

  1993cited by this paper

• DB-1310, a HER3-targeting antibody-drug conjugate, has synergistic anti-tumor activity with trastuzumab in HER2- and HER3-expressing breast cancer

  2025cites this paper
• Amelioration of breast cancer therapies through normalization of tumor vessels and microenvironment: paradigm shift to improve drug perfusion and nanocarrier permeation

  2024cites this paper
• Affinity of PET-MRI Tracers for Hypoxic Cells in Breast Cancer: A Systematic Review

  2024influential citation
• Dual anti-HER2/EGFR inhibition synergistically increases therapeutic effects and alters tumor oxygenation in HNSCC

  2024cites this paper
• The effect of tumor vascular remodeling and immune microenvironment activation induced by radiotherapy: quantitative evaluation with magnetic resonance/photoacoustic dual-modality imaging

  2023cites this paper
• Research Progress of Trastuzumab Targeted Therapy for HER2-Positive Breast Cancer

  2023cites this paper
• Bridging Scales: a Hybrid Model to Simulate Vascular Tumor Growth and Treatment Response

  2023cites this paper
• The Role of PET/CT in Breast Cancer

  2023cites this paper
• Nanotherapeutics Plus Immunotherapy in Oncology: Who Brings What to the Table?

  2022cites this paper
• Resistance to Trastuzumab

  2022cites this paper
• Modulation of the Tumor Microenvironment with Trastuzumab Enables Radiosensitization in HER2+ Breast Cancer

  2022cites this paper
• Evaluating the efficacy and microenvironment changes of HER2 + gastric cancer during HLX02 and Endostar treatment using quantitative MRI

  2022cites this paper
• Combined anti-angiogenic and cytotoxic treatment of a solid tumour: In silico investigation of a xenograft animal model's digital twin.

  2022cites this paper
• Optimizing combination therapy in a murine model of HER2+ breast cancer.

  2022cites this paper
• Quantifying Tumor Heterogeneity via MRI Habitats to Characterize Microenvironmental Alterations in HER2+ Breast Cancer

  2022cites this paper
• Quantifying the Effects of Combination Trastuzumab and Radiation Therapy in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer

  2020cites this paper
• Extracellular Matrix Features Discriminate Aggressive HER2-Positive Breast Cancer Patients Who Benefit from Trastuzumab Treatment

  2020cites this paper
• A hybrid model of tumor growth and angiogenesis: In silico experiments

  2020cites this paper
• Evaluating Trastuzumab in the treatment of HER2 positive breast cancer.

  2020cites this paper
• Anti-HER2 induced myeloid cell alterations correspond with increasing vascular maturation in a murine model of HER2+ breast cancer

  2020cites this paper
• Optimal Control Theory for Personalized Therapeutic Regimens in Oncology: Background, History, Challenges, and Opportunities

  2020cites this paper
• Multiparametric Analysis of Longitudinal Quantitative MRI Data to Identify Distinct Tumor Habitats in Preclinical Models of Breast Cancer

  2020cites this paper
• CD4 T-cell immune stimulation of HER2 + breast cancer cells alters response to trastuzumab in vitro

  2020cites this paper
• Innovation Research of the"Internet plus" Volleyball Teaching System in the Context of the Information Age

  2020cites this paper
• Endostar Rebuilding Vascular Homeostasis and Enhancing Chemotherapy Efficacy in Cervical Cancer Treatment

  2020cites this paper
• CD4 T-Cell Immune Stimulation of HER2+ Breast Cancer Cells in Response to Trastuzumab In Vitro

  2020cites this paper
• Experimentally-driven mathematical modeling to improve combination targeted and cytotoxic therapy for HER2+ breast cancer

  2019cites this paper
• Photoacoustic imaging for the evaluation of early tumor response to antivascular treatment.

  2019cites this paper
• Multiparametric MR for non‐invasive evaluation of tumour tissue histological characteristics after radionuclide therapy

  2019cites this paper
• Amniotic epithelial cells reverse abnormal vascular structure and function in endometrial carcinoma.

  2019cites this paper
• Alliance with EPR Effect: Combined Strategies to Improve the EPR Effect in the Tumor Microenvironment

  2019cites this paper
• Sepiapterin Enhances Tumor Radio- and Chemosensitivities by Promoting Vascular Normalization

  2018cites this paper
• The effects of intravoxel contrast agent diffusion on the analysis of DCE‐MRI data in realistic tissue domains

  2018cites this paper
• Characterizing Trastuzumab-Induced Alterations in Intratumoral Heterogeneity with Quantitative Imaging and Immunohistochemistry in HER2+ Breast Cancer

  2018cites this paper
• Mathematical modelling of trastuzumab-induced immune response in an in vivo murine model of HER2+ breast cancer.

  2018cites this paper
• Effects of peritumoral bevacizumab injection against oral squamous cell carcinoma in a nude mouse xenograft model: A preliminary study.

  2018cites this paper
• Precision Medicine with Imprecise Therapy: Computational Modeling for Chemotherapy in Breast Cancer

  2018cites this paper
• Preparation and Evaluation of Tibia- and Calvarium-Derived Decellularized Periosteum Scaffolds.

  2017cites this paper
• DCE‐ and DW‐MRI as early imaging biomarkers of treatment response in a preclinical model of triple negative breast cancer

  2017cites this paper
• Quantitative [18F]FMISO PET Imaging Shows Reduction of Hypoxia Following Trastuzumab in a Murine Model of HER2+ Breast Cancer

  2017cites this paper
• Multiparametric MRI for evaluation of tumour treatment response

  2016cites this paper